This bulletin covers aspects of breast cancer, and should be of interest to multidisciplinary teams working in this area.
Sections can include:
· Combined Modality Therapies
· Drug Therapy
· Pathology, Staging, Polymorphisms & Biomarkers
· Prognosis, Survival & Risk Factors
· Radiotherapy & Imaging
· Supportive Care & Symptom Management
· Surgery
Many of the following articles are available online via the NHS Scotland Knowledge Network. Please use the links where provided and your ATHENS password. A complete list of available online journals and registration for ATHENS can be found at www.knowledge.scot.nhs.uk/
If the article you require is not available via the NHS Scotland Knowledge Network and you would like to request a print copy, please submit your request online at www.quest.scot.nhs.uk
This bulletin contains a selection of material gathered from a search of the evidence base, and is not intended to be comprehensive. Professional judgment should be exercised when appraising the material. The Library takes no responsibility for the wording, content and accuracy of the information supplied, which has been extracted in good faith from reputable sources. NHSGGC is not responsible for the content of external internet sites.
Compiled by:
Kirsty Coltart
Subject Librarian
Beatson West of Scotland Cancer Centre
0141 301 7285,
GENERAL
Gradishar, W.J., Anderson, B.O., Balassanian, R., et al. (2016). Invasive Breast Cancer Version 1.2016, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network 14,3:324-354.
Paluch-Shimon, S., Pagani, O., Partridge, A.H., et al. (2016). Second international consensus guidelines for breast cancer in young women (BCY2). Breast 26,87-99.
Thomssen, C., Augustin, D., Ettl, J., et al. (2016). ABC3 Consensus: Assessment by a German Group of Experts. Breast Care 11,1:61-70.
COMBINED MODALITY THERAPIES
Datta, N.R., Puric, E., Klingbiel, D., et al. (2016). Hyperthermia and Radiation Therapy in Locoregional Recurrent Breast Cancers: A Systematic Review and Meta-analysis. International journal of radiation oncology, biology, physics 94,5:1073-1087.
Forbes, J.F., Sestak, I., Howell, A., et al. (2016). Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial. Lancet 387,10021:866-873.
Ganz, P.A., Cecchini, R.S., Julian, T.B., et al. (2016). Patient-reported outcomes with anastrozole versus tamoxifen for postmenopausal patients with ductal carcinoma in situ treated with lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial. Lancet 387,10021:857-865.
Margolese, R.G., Cecchini, R.S., Julian, T.B., et al. (2016). Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial. Lancet 387,10021:849-856.
DRUG & TARGETED THERAPY
Aftimos, P., Polastro, L., Ameye, L., et al. (2016). Results of the Belgian expanded access program of eribulin in the treatment of metastatic breast cancer closely mirror those of the pivotal phase III trial. European journal of cancer 60,117-124.
Bellet, M., Gray, K.P., Francis, P.A., et al. (2016). Twelve-Month Estrogen Levels in Premenopausal Women With Hormone Receptor-Positive Breast Cancer Receiving Adjuvant Triptorelin Plus Exemestane or Tamoxifen in the Suppression of Ovarian Function Trial (SOFT): The SOFT-EST Substudy. Journal of Clinical Oncology 34,14:1584-1593.
Bonnefoi, H., Grellety, T., Tredan, O., et al. (2016). A phase II trial of abiraterone acetate plus prednisone in patients with triple-negative androgen receptor positive locally advanced or metastatic breast cancer (UCBG 12-1). Annals of Oncology 27,5:812-818.
Burstein, H.J., Lacchetti, C., Anderson, H., et al. (2016). Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update on Ovarian Suppression. Journal of Clinical Oncology 34,14:1689-1701.
Chan, A., Delaloge, S., Holmes, F.A., et al. (2016). Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncology 17,3:367-377.
Chavez-MacGregor, M., Clarke, C.A., Lichtensztajn, D.Y., et al. (2016). Delayed Initiation of Adjuvant Chemotherapy Among Patients With Breast Cancer. JAMA Oncology 2,3:322-329.
Coombes, R.C., Kilburn, L.S., Tubiana-Mathieu, N., et al. (2016). Epirubicin dose and sequential hormonal therapy-Mature results of the HMFEC randomised phase III trial in premenopausal patients with node positive early breast cancer. European journal of cancer 60,146-153.
Freedman, R.A., Gelman, R.S., Wefel, J.S., et al. (2016). Translational Breast Cancer Research Consortium (TBCRC) 022: A Phase II Trial of Neratinib for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases. Journal of Clinical Oncology 34,9:945-952.
Graham, J., Pitz, M., Gordon, V., et al. (2016). Clinical predictors of benefit from fulvestrant in advanced breast cancer: A Meta-analysis of randomized controlled trials. Cancer treatment reviews 45,1-6.
Janni, W., Harbeck, N., Rack, B., et al. (2016). Randomised phase III trial of FEC120 vs EC-docetaxel in patients with high-risk node-positive primary breast cancer: final survival analysis of the ADEBAR study. British journal of cancer 114,8:863-871.
Kadakia, K.C., Snyder, C.F., Kidwell, K.M., et al. (2016). Patient-Reported Outcomes and Early Discontinuation in Aromatase Inhibitor-Treated Postmenopausal Women With Early Stage Breast Cancer. Oncologist 21,5:539-546.
Mobus, V. (2016). Adjuvant Dose-Dense Chemotherapy in Breast Cancer: Standard of Care in High-Risk Patients. Breast Care 11,1:8-12.
Rampurwala, M., Wisinski, K.B. and O'Regan, R. (2016). Role of the androgen receptor in triple-negative breast cancer. Clinical Advances in Hematology & Oncology 14,3:186-193.
Reyes, S.A., King, T.A., Fei, K., et al. (2016). Factors Affecting the Completion of Adjuvant Chemotherapy in Early-Stage Breast Cancer. Annals of Surgical Oncology 23,5:1537-1542.
Ribi, K., Luo, W., Bernhard, J., et al. (2016). Adjuvant Tamoxifen Plus Ovarian Function Suppression Versus Tamoxifen Alone in Premenopausal Women With Early Breast Cancer: Patient-Reported Outcomes in the Suppression of Ovarian Function Trial. Journal of Clinical Oncology 34,14:1601-1610.
Ryden, L., Heibert Arnlind, M., Vitols, S., et al. (2016). Aromatase inhibitors alone or sequentially combined with tamoxifen in postmenopausal early breast cancer compared with tamoxifen or placebo - Meta-analyses on efficacy and adverse events based on randomized clinical trials. Breast 26,106-114.
Shiba, E., Yamashita, H., Kurebayashi, J., et al. (2016). A randomized controlled study evaluating safety and efficacy of leuprorelin acetate every-3-months depot for 2 versus 3 or more years with tamoxifen for 5 years as adjuvant treatment in premenopausal patients with endocrine-responsive breast cancer. Breast Cancer 23,3:499-509.
Smith, S.G., Sestak, I., Forster, A., et al. (2016). Factors affecting uptake and adherence to breast cancer chemoprevention: a systematic review and meta-analysis. Annals of Oncology 27,4:575-590.
Truong, J., Lee, E.K., Trudeau, M.E., et al. (2016). Interpreting febrile neutropenia rates from randomized, controlled trials for consideration of primary prophylaxis in the real world: a systematic review and meta-analysis. Annals of Oncology 27,4:608-618.
Twelves, C., Jove, M., Gombos, A., et al. (2016). Cytotoxic chemotherapy: Still the mainstay of clinical practice for all subtypes metastatic breast cancer. Critical Reviews in Oncology-Hematology 100,74-87.
Untch, M., Jackisch, C., Schneeweiss, A., et al. (2016). Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto-GBG 69): a randomised, phase 3 trial. Lancet Oncology 17,3:345-356.
Zdenkowski, N., Forbes, J.F., Boyle, F.M., et al. (2016). Observation versus late reintroduction of letrozole as adjuvant endocrine therapy for hormone receptor-positive breast cancer (ANZ0501 LATER): an open-label randomised, controlled trial. Annals of Oncology 27,5:806-812.
PATHOLOGY, STAGING, POLYMORPHISMS, BIOMARKERS
Bartlett, J.M.S., Bayani, J., Marshall, A., et al. (2016). Comparing Breast Cancer Multiparameter Tests in the OPTIMA Prelim Trial: No Test Is More Equal Than the Others. Journal of the National Cancer Institute 108,9:
Harris, L.N., Ismaila, N., McShane, L.M., et al. (2016). Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline. Journal of Clinical Oncology 34,10:1134-1150.
Yang, S.X., Polley, E. and Lipkowitz, S. (2016). New insights on PI3K/AKT pathway alterations and clinical outcomes in breast cancer. Cancer treatment reviews 45,87-96.
PROGNOSIS, SURVIVAL, RISK FACTORS
Colleoni, M., Sun, Z., Price, K.N., et al. (2016). Annual Hazard Rates of Recurrence for Breast Cancer During 24 Years of Follow-Up: Results From the International Breast Cancer Study Group Trials I to V. Journal of Clinical Oncology 34,9:927-935.
Lee, E.S., Jung, S.Y., Kim, J.Y., et al. (2016). Identifying the potential long-term survivors among breast cancer patients with distant metastasis. Annals of Oncology 27,5:828-833.
Schoenberger, Y., Benz, R., McNees, P., et al. (2016). Patient-centered outcome evaluation of the Rural Breast Cancer Survivors Intervention. Supportive Care in Cancer 24,4:1841-1848.
RADIOTHERAPY AND IMAGING
Bloomquist, E.V., Ajkay, N., Patil, S., et al. (2016). A Randomized Prospective Comparison of Patient-Assessed Satisfaction and Clinical Outcomes with Radioactive Seed Localization versus Wire Localization. Breast Journal 22,2:151-157.
Coombs, N.J., Coombs, J.M., Vaidya, U.J., et al. (2016). Environmental and social benefits of the targeted intraoperative radiotherapy for breast cancer: data from UK TARGIT-A trial centres and two UK NHS hospitals offering TARGIT IORT. BMJ Open 6,5:e010703.
Cooper, B.T., Formenti-Ujlaki, G.F., Li, X., et al. (2016). Prospective Randomized Trial of Prone Accelerated Intensity Modulated Breast Radiation Therapy With a Daily Versus Weekly Boost to the Tumor Bed. International journal of radiation oncology, biology, physics 95,2:571-578.
Finkel, M.A., Cooper, B.T., Li, X., et al. (2016). Quality of Life in Women Undergoing Breast Irradiation in a Randomized, Controlled Clinical Trial Evaluating Different Tumor Bed Boost Fractionations. International journal of radiation oncology, biology, physics 95,2:579-589.
Garcia, E.M., Crowley, J., Hagan, C., et al. (2016). Evolution of Imaging in Breast Cancer. Clinical Obstetrics & Gynecology 59,2:322-335.
Haviland, J.S., Hopwood, P., Mills, J., et al. (2016). Do Patient-reported Outcome Measures Agree with Clinical and Photographic Assessments of Normal Tissue Effects after Breast Radiotherapy? The Experience of the Standardisation of Breast Radiotherapy (START) Trials in Early Breast Cancer. Clinical Oncology (Royal College of Radiologists) 28,6:345-353.
Hylton, N.M., Gatsonis, C.A., Rosen, M.A., et al. (2016). Neoadjuvant Chemotherapy for Breast Cancer: Functional Tumor Volume by MR Imaging Predicts Recurrence-free Survival-Results from the ACRIN 6657/CALGB 150007 I-SPY 1 TRIAL. Radiology 279,1:44-55.
Iacconi, C., Galman, L., Zheng, J., et al. (2016). Multicentric Cancer Detected at Breast MR Imaging and Not at Mammography: Important or Not?. Radiology 279,2:378-384.
Juneja, P., Bonora, M., Haviland, J.S., et al. (2016). Does breast composition influence late adverse effects in breast radiotherapy?. Breast 26,25-30.
Konig, J., van Ewijk, R., Kuhr, K., et al. (2016). Radiotherapy effects on early breast cancer survival in observational and randomized studies: a systematic analysis of advantages, disadvantages and differences between the two study types. Breast Cancer 23,3:415-424.
Lange, M., Reimer, T., Hartmann, S., et al. (2016). The role of specimen radiography in breast-conserving therapy of ductal carcinoma in situ. Breast 26,73-79.
Maxwell, A.J., Bundred, N.J., Harvey, J., et al. (2016). A randomised pilot study comparing 13 G vacuum-assisted biopsy and conventional 14 G core needle biopsy of axillary lymph nodes in women with breast cancer. Clinical radiology 71,6:551-557.
Rominger, M., Berg, D., Frauenfelder, T., et al. (2016). Which factors influence MRI-pathology concordance of tumour size measurements in breast cancer?. European radiology 26,5:1457-1465.
Verma, V., Vicini, F., Tendulkar, R.D., et al. (2016). Role of Internal Mammary Node Radiation as a Part of Modern Breast Cancer Radiation Therapy: A Systematic Review. International journal of radiation oncology, biology, physics 95,2:617-631.
Yamauchi, C., Sekiguchi, K., Nishioka, A., et al. (2016). The Japanese Breast Cancer Society Clinical Practice Guideline for radiation treatment of breast cancer, 2015 edition. Breast Cancer 23,3:378-390.
Zhu, Y., Zhou, W., Zhou, J., et al. (2016). Axillary Staging of Early-Stage Invasive Breast Cancer by Ultrasound-Guided Fine-Needle Aspiration Cytology: Which Ultrasound Criteria for Classifying Abnormal Lymph Nodes Should Be Adopted in the Post-ACOSOG Z0011 Trial Era?. Journal of Ultrasound in Medicine 35,5:885-893.
SUPPORTIVE CARE AND SYMPTOM MANAGEMENT
Ahmed, K., Marchand, E., Williams, V., et al. (2016). Development and pilot testing of a psychosocial intervention program for young breast cancer survivors. Patient Education & Counseling 99,3:414-420.
Beesley, H., Goodfellow, S., Holcombe, C., et al. (2016). The intensity of breast cancer patients' relationships with their surgeons after the first meeting: Evidence that relationships are not 'built' but arise from attachment processes. European Journal of Surgical Oncology 42,5:679-684.
Boyle, T., Vallance, J.K., Ransom, E.K., et al. (2016). How sedentary and physically active are breast cancer survivors, and which population subgroups have higher or lower levels of these behaviors?. Supportive Care in Cancer 24,5:2181-2190.
Cheung, Y.T., Ong, Y.Y., Ng, T., et al. (2016). Assessment of mental health literacy in patients with breast cancer. Journal of Oncology Pharmacy Practice 22,3:437-447.
Chiu, H., Shyu, Y., Chang, P., et al. (2016). Effects of Acupuncture on Menopause-Related Symptoms in Breast Cancer Survivors: A Meta-analysis of Randomized Controlled Trials. Cancer nursing 39,3:228-237.
Cho, Y., Do, J., Jung, S., et al. (2016). Effects of a physical therapy program combined with manual lymphatic drainage on shoulder function, quality of life, lymphedema incidence, and pain in breast cancer patients with axillary web syndrome following axillary dissection. Supportive Care in Cancer 24,5:2047-2057.
Cornette, T., Vincent, F., Mandigout, S., et al. (2016). Effects of home-based exercise training on VO2 in breast cancer patients under adjuvant or neoadjuvant chemotherapy (SAPA): a randomized controlled trial. European journal of physical & rehabilitation medicine 52,2:223-232.
Eda, K., Uzer, K., Murat, T., et al. (2016). The effects of enteral glutamine on radiotherapy induced dermatitis in breast cancer. Clinical Nutrition 35,2:436-439.
Farthmann, J., Hanjalic-Beck, A., Veit, J., et al. (2016). The impact of chemotherapy for breast cancer on sexual function and health-related quality of life. Supportive Care in Cancer 24,6:2603-2609.
Giron, P.S., Haddad, C.A.S., Lopes de Almeida Rizzi,Samantha Karlla, et al. (2016). Effectiveness of acupuncture in rehabilitation of physical and functional disorders of women undergoing breast cancer surgery. Supportive Care in Cancer 24,6:2491-2496.
Goldberg, D.R., Wardell, D.W., Kilgarriff, N., et al. (2016). An Initial Study Using Healing Touch for Women Undergoing a Breast Biopsy. Journal of Holistic Nursing 34,2:123-134.